Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol in Compensated Advanced Chronic Liver Disease
NCT06449339Phase 4Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Jul 2024
- Primary completion
- Jul 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of carvedilol in chronic liver disease (CLD), Portal Hypertension (PH), sponsored by The Chinese University of Hong Kong. Started Jul 2024; status: recruiting.
02
Drugs
carvedilol
03
Conditions
chronic liver disease (CLD)Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT06449339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449339.